Pangenomic unit working on real-world evidence platform

Mr. Robert Nygren reports PANGENOMIC HEALTH TO LAUNCH REAL-WORLD EVIDENCE PLATFORM FOR COMPLEMENTARY & ALTERNATIVE MEDICINE THROUGH MINDLEAP HEALTH SUBSIDIARY Pangenomic Health Inc.'s wholly owned subsidiary, Mindleap Health Inc., is developing a real-world evidence (RWE) platform for the complementary and alternative medicine (CAM) market. "With profound changes taking place in the U.S. Food and Drug Administration and National Institutes of Health by Robert F. Kennedy Jr., the Secretary of Health and Human Services, we believe there is a significant opportunity to develop a global evidence-based platform that collects information about the efficacy of non-pharmaceutical approaches to health and wellness," said Robert Nygren, executive chair of Pangenomic Health and newly appointed president of its wholly owned subsidiary, Mindleap Health. "These changes in the U.S. now complement decades-long advocacy efforts by the World Health Organization for national health authorities to adopt greater use of CAM solutions as a means to lower health care costs and improve health outcomes globally." On July 25, 2025, the company announced the development of the NaraCare.AI platform for personalized health products, which will leverage insights and functionality developed from the company's Nara mental health app, Mindleap telehealth platform and Mujn diagnostic tools and will utilize leading large language model (LLM) platforms. The Mindleap telehealth platform is designed to provide consumers with on-line access to an extensive library of wellness content and with telehealth access to a broad range of alternative health practitioners. The company further announced on Aug. 19, 2025, that its Agenta Health e-commerce site will be the springboard for the NaraCare.AI platform. The new Mindleap RWE platform will collect and analyze health data from a broad range of traditional and non-traditional sources, including clinical research studies from Western and non-Western countries, long-documented history of human use, and evidence of modern use. Leveraging leading LLM platforms that can analyze these health data sets, the Mindleap RWE platform will aim to support an expanded interpretation of the substantial evidence standard needed to support health claims. First established by the FDA (U.S. Food and Drug Administration) for new drug approvals in 1962, the substantial evidence standard has recently expanded beyond traditional randomized, double-blind studies to include some real-world evidence of drug candidate efficacy. The goal of the Mindleap RWE platform will be to become a trusted source of information about non-pharmaceutical health solutions. Insights from the Mindleap RWE platform will be utilized within the NaraCare.AI platform to support its personalized product recommendation functionality for consumers and also be available on a subscription basis to manufacturers, distributors, retailers, researchers and health practitioners interested in understanding the level of evidence that exists for complementary and alternative medicine health and wellness solutions. Mindleap Health expects to launch the Mindleap RWE platform in the first quarter of 2026. About Mindleap Health Inc. Mindleap Health is a provider of holistic health and wellness information. About Pangenomic Health Inc. Pangenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. Registered as a British Columbia benefit company, Pangenomic Health's mission is to promote alternative health solutions tailored to the health profile of each individual. We seek Safe Harbor.